Pelabresib is a small molecule commercialized by MorphoSys, with a leading Phase III program in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to Globaldata, it is involved in 5 clinical trials, of which 2 were completed, and 3 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Pelabresib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Pelabresib is expected to reach an annual total of $240 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Pelabresib (CPI-0610) is under development for the treatment of acute myelocytic leukemia (AML, Acute Myeloblastic Leukemia), myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasms myelofibrosis, primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. The drug candidate is administered orally and is a new molecular entity. It acts by targeting bromodomain and extra-terminal (BET) proteins (BRD2, BRD3, BRD4, and BRDT). It was also under development for the treatment of non-Hodgkin lymphomas including diffuse large cell B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, multiple myeloma.
MorphoSys is commercial-stage biopharmaceutical company that develop monoclonal antibodies for therapeutic and research applications, with focused on the treatment of cancer and autoimmune diseases. The company’s product pipeline includes tafasitamab, pelabresib, cpi-0209, gantenerumab, otilimab, ianalumab, abelacimab, felzartamab, setrusumab, NOV-8, NOV-14 and MOR210. Its Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody directed against CD19 in clinical development for the treatment of B cell malignancies. The company provides clinical trials for cancer and inflammatory disorders. MorphoSys also conducts research and development activities with pharmaceutical and biotechnology companies. The company owns a regional licensing agreement to develop and commercialize products. It operates in the US. MorphoSys is headquartered in Planegg, Bayern, Germany.
The company reported revenues of (Euro) EUR179.6 million for the fiscal year ended December 2021 (FY2021), a decrease of 45.2% over FY2020. The operating loss of the company was EUR506.2 million in FY2021, compared to an operating profit of EUR26.7 million in FY2020. The net loss of the company was EUR514.5 million in FY2021, compared to a net profit of EUR97.9 million in FY2020. The company reported revenues of EUR95.8 million for the third quarter ended September 2022, an increase of 61.1% over the previous quarter.
For a complete picture of Pelabresib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.